-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor
.
GBM patients receiving standard treatment, including surgical resection, chemotherapy and radiotherapy, have a median survival time of approximately 15 months
Oncolytic virus (OV) provides a potentially unique treatment for GBM because its mechanism of action is completely different from the standard treatment of GBM
.
Tumor lytic herpes simplex virus-1 (oHSV) is one of the most widely studied oncolytic viruses.
Selectively lyse cancer cells while leaving normal cells basically unchanged Selectively lyse cancer cells while leaving normal cells basically unchanged
Talimogene laherparepvec (Imlygic) is the first oncolytic virus therapy approved by the FDA and is based on the oHSV vector
.
In existing studies, researchers have found that oHSV treatment greatly increases the intratumoral infiltration of immune cells
αCD47-G1, but not αCD47-G4, can induce the cytotoxicity of human NK cells to GBM cells
.
.
αCD47-G1, but not αCD47-G4, can induce the cytotoxicity of human NK cells to GBM cells
Oncolytic herpes virus expressing full- length anti-(α)-human CD47 IgG1 or IgG4 antibody Oncolytic herpes virus expressing full-length anti-(α)-human CD47 IgG1 or IgG4 antibody
ΑCD47-IgG1 intracranial injection of virus produced in the tumor microenvironment sustained release of the corresponding antibodies, but does not enter the systemic circulation ; In addition, generating αCD47-IgG1 virus to provide better survival rate of tumor-bearing mice high
.
The results from a mouse tumor model with strong immunity further confirmed that macrophages, and to a lesser extent NK cells, mediate the anti-tumor cytotoxicity of the oncolytic herpes virus that produces antibodies
The virus produced by intracranial injection of αCD47-IgG1 continuously releases the corresponding antibody in the tumor microenvironment, but does not enter the systemic circulation .
Original source:
Original source:Bo Xu al.
Bo Xu al.
Leave a message here
